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ABSTRACT
Severe gingival enlargement (GE) is one of the most commonly observed adverse effects in patients who have
undergone renal transplants due to the use of cyclosporine A. Objectives: We aimed to gain more insight into the
prevalence of GE in patients with renal transplants. Methods: We searched the PubMed and Web of Science databases
for relevant studies from January 1990 to January 2018. Using random effects models, we calculated summary
incidence rates and 95% confidence intervals (CIs). Results: A total of 595 patients from 10 studies were included.
Patients using cyclosporine A with or without any other drugs had a 62.6% (95% CI, 41.9%–79.5%) incidence of
GE. Subgroup analysis according to diagnostic criteria showed that the incidence of GE was lower when using
well-defined diagnostic criteria or scoring system. The incidence of GE was 88.2% (95% CI, 80.9%–93.0%) in
patients using cyclosporine A with nifedipine. Cyclosporine A without nifedipine was associated with a significantly
decreased risk of GE incidence when compared with the combination of cyclosporine A and nifedipine (odds ratio:
0.198; 95% CI, 0.083–0.473; P < 0.001). Conclusions: It is important for all clinicians to know the effects of the
aforementioned drugs and the treatment options.
Key words: cyclosporine A, gingival enlargement, gingival overgrowth, renal transplantation
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INTRODUCTION
Gingival enlargement (GE) is defined as medicationrelated gingival overgrowth or gingival hyperplasia.1
First reported in 1939 by Kimball,2 drug-induced GE
occurred with the chronic usage of phenytoin, an
antiepileptic drug. Drug-induced GE occurs as a result
of using three drug types: antiepileptic drugs, such as
phenytoin; immunosuppressants, such as cyclosporine
A; and calcium channel blockers, such as nifedipine,
diltiazem, or verapamil, that are used to treat different
cardiovascular disorders.3 These drugs accumulate in
the extracellular matrix of gingival connective tissue,
especially in the collagenous component, with several
levels of chronic inflammation.4
Cyclosporin A is the first preference immunosuppressant
agent to avoid allograft rejection in patients with organ
transplantation. Cyclosporin A is also applied to treat
some autoimmune diseases such as type I diabetes,
psoriasis, systemic lupus erythematosus, rheumatoid
arthritis and multiple sclerosis.5 In patients who use
Cyclosporin A, hypertension is frequently observed
and calcium antagonists such as nifedipine, diltiazem

and verapamil are commonly given to treat this
condition. These drugs have been reported that they
cause GE.6-8 Nifedipine is the most commonly used as
calcium antagonist drug for the treatment of transplant
patients with hypertension and at the same time it
decreases Cyclosporin A -induced nephrotoxicity.9
GE can occur in the first 6 months after transplantation,
and clinical appearance ranges from small variations in
gingival papilla to total coverage of the dental crown,
usually occurring in the vestibular face of the teeth.10
GE can cause impaired oral functioning, delayed and/
or ectopic tooth eruption, speech difficulties, headache,
and difficulty in maintaining oral hygiene, resulting in
an increased tendency to infections, tooth decay, and
periodontal disorders.11 Impaired oral hygiene is a risk
for the development of oral sepsis, which is potentially
serious in immunocompromised patients.12
The most efficient treatment for drug-induced GE is
withdrawing or replacing the medication.1 The aim of
this study is to increase insight into the prevalence of
GE in patients who have undergone renal transplant
using a meta-analysis.
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METHODS
This systematic review and meta-analysis was designed
and performed in accordance with the Meta-analysis Of
Observational Studies in Epidemiology criteria13 for
observational studies.
Data sources and search strategy
Both of the study investigators designed and conducted
the search strategy. We systematically searched the
PubMed database using the terms “renal transplant OR
kidney transplant OR kidney allograft OR renal allograft”
AND “gingival hyperplasia OR gingival hypertrophy
OR gingival overgrowth OR oral manifestation OR
oral lesion OR oral cavity OR gingival enlargement
OR oral findings OR mucocutaneous manifestations
OR oral mucosal lesion OR gingival status OR oral
health OR gum hyperplasia OR gum hypertrophy OR
gum overgrowth OR gum enlargement OR gingival
changes OR gum changes OR gingival health” AND
“pediatric OR children OR juvenile OR adolescent.”
In addition, we manually screened reference lists of
original and review articles. The final literature search
was performed on February 15, 2018.

Figure 1. Flow chart of study selection process in the metaanalysis

Study selection
Studies fulfilling the following criteria were included:
(1) published as full-length articles in English, (2) casecontrol studies, cohort studies, or clinical trial cohort
studies (prospective or retrospective, regardless of
sample size and follow-up duration), (3) available data
regarding post-transplantation drug regimen, sample
size, and incidence of GE with specific drug regimen(s),
and (4) included and reported data for children aged
<18 years.

Outcomes assessed
The incidence rate was calculated by dividing the total
number of new cases of GE by the total number of
patients, and the proportion of patients with GE and
95% confidence intervals (CIs) were derived for each
study. Our primary analysis focused on assessing GE
incidence after exposure to immunsupressive agents.

Studies meeting the following criteria were excluded:
(1) abstracts, letters to the editor, reviews, and case
reports, and (2) if there were < three studies evaluating
and reporting the incidence of GE for a specific drug
regimen.
All articles were screened first by title, then by abstract,
and finally by full text according to the inclusion and
exclusion criteria. Full texts were reviewed when the
title or abstract met the selection criteria or when the
status (include or exclude) could not be determined from
the title and/or abstract alone.
Data extraction and quality evaluation
Data were extracted from all of the included articles
by one author (NÖ), and another author independently
reviewed the data for accuracy and completeness (GS).
Discrepancies between the reviewers were resolved
by consensus. The following data were extracted:
study setting and design, name of the first author,
year of publication, sample size, months of follow-

up, mean age, adverse outcomes of interest (GE), and
strategies for confirming GE cases. The quality of the
included observational studies was evaluated using
the Newcastle–Ottawa Scale14, and the quality of the
included interventional studies was evaluated with
the Methodological index for non-randomized studies
(MINORS) scale15.

Statistical analysis
We calculated weighted summary estimates using
generalized inverse variance with random-effects
models as described by DerSimonian and Laird.16
Heterogeneity within groups was assessed with the I2
statistic, which estimates the proportion of total variation
across studies that is due to heterogeneity in study
patients, design, or interventions rather than chance;
I2 values >50% suggest substantial heterogeneity. A
probability level < 0.05 was considered statistically
significant for all tests (except for heterogeneity).
Heterogeneity was considered statistically significant
when P < 0.1. All statistical analyses were performed
using version 2 of the Comprehensive Meta-Analysis
program (Biostat, Englewood, NJ, USA). Publication
bias was assessed by funnel plots, and all P values
were 2-tailed. Potential publication bias was assessed
by funnel plots and Egger regression asymmetry test.
Subgroup analyses
We investigated the reasons for heterogeneity on
subgroup analyses when significant and substantial
heterogenity was detected between studies.
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Table 1. Study characteristics and quality scores
Authors/Year Study type

Treatment arms Patients Mean Gingival
Gingival enlarnumber Age
enlargement gement diagnoincidence
sis/ Diagnoser

Prior drug
history

Quality
score

Ellis D. et
al.38

Case control
study

CsA+MinnesotaALG+prednisone+AZT

Menni S.
et al.39

24

9.8

20/23

Not reported

≥15 months

5

Cross Sectional CsA±
study
Prednisone±
AZT

28

12.8

26/28

Not reported

≥1 months

5

Webb N.J.A.
et al.35

Cross sectional CsA±AZT±
study
MMF±
Prednisolone±
Sirolimus

33

13

4/33

Seymour system/ ≥6 months
Dentist

6

Farge P.
et al.36

Cross sectional CsA
study

106

9.6

44/106

Nunn grading/
Dentist

≥6 months

6

Silverstein
D.M
et al.33

Interventional
study

24

14.8

22/24

StableIncreasedDecreased/ Family report

≥6 months

9

Wondimu B.
et al.40

Cross sectional CsA+ predniso- 32
study
lone±AZT

10

4/32

Sulcus probing
≥12 months
depth ≥4mm without periodontal
attachment loss
Positive /
Dentist

6

Karpinia
K.A.
et al.31

Cross sectional CsA
19
study
CsA+nifedipine 30

12.5

13/19

PresentAbsent/ Dentist

5

Bökenkamp
A.
et al.29

Interventional
study

16

Elias D.
et al.30

Cross sectional CsA+ predniso- 25
study
ne+ AZT

CsA+Nifedipine+ Prednisone+ AZT/MMF

CsA+ predniso- 35
ne ±AZT

25/30
18/35

CsA+nifedipi52
ne+prednisone±
AZT

Cross sectional CsA+ predniso- 167
study
ne+ AZT/MMF

Mcgaw grading/ ≥12 months
Dentist

14

Not reported

≥6 months

6

Not reported

Not reported 4

46/52

14.3

CsA+ predniso- 21
ne+ AZT+nifedipine
Prokurat S.
et al.32

≥1 months

19/25
21/21

11.5

%28

RESULTS
Literature search results
A total of 644 records were identified according
to the search strategy. Overall, 588 articles were
excluded after removing duplicates, titles, and abstract
screenings. We screened the full texts of the remaining
56 articles, and 10 studies met the inclusion criteria
(Figure 1). We conducted 3 different analyses from
these 10 studies: (1) we calculated GE incidence for
patients treated with cyclosporine A with or without any
other drugs; (2) we calculated GE incidence for patients
treated with cyclosporine A along with nifedipine as

the main antihypertensive with or without any other
drugs; and (3) we calculated odds ratios for GE outcome
between patients taking cyclosporine with and without
nifedipine.
Study Characteristics and quality
Table 1 shows the characteristics of patients and studies.
The quality of the included observational studies was
generally fair, with Newcastle–Ottawa Scale values
between 5 and 6. Moreover, the quality of the included
noncontrolled interventional studies was generally fair,
with MINORS Scale values between 9 and 14.
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Figure 4. Forest (A) and funnel (B) plots of gingival
enlargement risk in patients using cyclosporine A and
nifedipine versus those using cyclosporine but not nifedipine
following renal transplant surgery

Figure 2. Forest (A) and funnel (B) plots of gingival
enlargement incidence on meta-analysis in patients using
cyclosporine A as the primary immunsuppressive treatment
following renal transplant surgery

= 93.6%). Funnel plot asymmetry was evident on visual
inspection (Figure 2B), but the Egger regression test
did not indicate a potential publication bias (P = 0.19).
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Figure 3. Forest (A) and funnel (B) plots of gingival
enlargement incidence on meta-analysis in patients using
cyclosporine A as the primary immunosuppressive along
with nifedipine as antihypertensive treatment following renal
transplant surgery

Gingival enlargement incidence in patients using
cyclosporine as the primary post-transplant immunsupressive
For this incidence analysis, patients who received cyclosporine as the primary post-transplant immunosuppressive were included regardless of whether any additional
immunosuppressives or antihypertensives were used. A
total of 595 patients from 10 trials were included in the
analysis: GE was reported in 309 of 595 subjects with
a pooled incidence of 62.6% (95% CI, 41.9%–79.5%,
Figure 2A) with significant heterogeneity (P < 0.001; I2

4

Next, we conducted subgroup analysis to investigate the
incidence of heterogeneity between studies. There was
no significant difference in the interval between renal
transplantation and gingival evaluation (≥6 months vs.
<6 months) (P = 0.921) between the subgroups, and
there was also no significant difference between the
subgroups based on GE diagnoser (dentist versus other/
nonreported) (P = 0.066). However, subgroup analysis
on GE diagnostic criteria (any defined enlargement
scoring vs. not defined/not reported) revealed a
significant difference between the 2 subgroups (P =
0.029), and well-defined diagnostic criteria or scoring
system evoked less GE incidence reporting. This
analysis reports the significant heterogeneity seen in
the overall analysis.
Gingival enlargement incidence in patients using
cyclosporine as the primary post-transplant immunosuppressive and nifedipine as the antihypertensive
agent
For this incidence analysis, patients who received cyclosporine as the primary post-transplant immunosuppressive and nifedipine as an antihypertensive agent
were included regardless of their use of any additional
immunosuppressives or antihypertensives. We included
a total of 127 patients from 4 trials in the analysis. GE
was reported in 114 of 127 subjects with a pooled incidence of 88.2% (95% CI, 80.9%–93.0%, Figure 3A)
with insignificant heterogeneity (P = 0.485; I2 = 0%).
Symmetrical funnel plots were noted on visual inspection (Figure 3B), and potential publication bias was
not indicated on the Egger regression test (P = 0.146).
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Cyclosporine A without nifedipine versus cyclosporine A with nifedipine in terms of gingival enlargement
Meta-analysis results of the 3 studies revealed that
cyclosporine A without nifedipine was associated with
a significantly increased risk of GE incidence when
compared to the combination of cyclosporine A with
nifedipine (odds ratio: 0.198; 95% CI, 0.083–0.473; P <
0.001) (Figure 4A), with insignificant heterogeneity (P =
0.336; I2 = 8.2%). The funnel plot was symmetrical on
visual inspection (Figure 4B), and the Egger regression
test did not indicate a potential publication bias (P =
0.853).

DISCUSSION
When used logically, meta-analysis is a powerful
method although its application includes many caveats.
There is no doubt that meta-analysis is an important
method in medical research, clinical practice, and
public policy.17 The most important aim of a literature
review may be planning the study for a subject, and the
author may also learn new ideas from previous studies
or mistakes. Thus, this information may be considered
in preparing a new research article.18
This meta-analysis included 10 articles on the prevalence
of drug-induced GE. The articles were evaluated for
the risk of bias. The potential for publication bias was
determined using funnel plots and Egger regression test.
Potential publication bias was not found in studies that
were analyzed using the three different methods.
A major limitation of our meta-analysis was that the
evaluated studies had different study populations and
samples, different diagnostic methods, and different
types of drugs. Heterogeneity within groups was
assessed with the I2 statistic. No significant difference
between subgroups was found based on the diagnostic
method for GE.
The prevalence of GE mainly occurs due to use of
cyclosporine A and/or nifedipine.19 The pathogenesis of
drug-induced GE is not clear, but several mechanisms
have been suggested. The clinical appearance
and histological features of GE due to phenytoin,
cyclosporine, and calcium antagonists are significantly
similar, although there are extensive differences in
their corresponding chemical patterns. Thereby, some
authors11,20,21 suggest that gingival alterations can be a
result of metabolic biotransformation of the drug rather
than the drug result itself. Metabolites of these drugs
can be involved and behave in a similar manner.11,20,21
The prevalence of GE among users of cyclosporine
A was reported to range from 20% to 45%. Calcium
channel blockers were associated with exacerbation.22,23
In our meta-analysis, the prevalence estimates of

studies were between 12.1% and 100%, which may
be explained by differences in the number of patients,
incorrect assessment, and different local etiological
situations. The combined use of cyclosporine A
and nifedipine for treatment is firstly prescribed in
approximately 60% of renal allograft recipients,24 and
although there are opposing opinions,25 some authors
have reported an increase in prevalence and/or severity
of GE in transplant patients.24,26,27 A significant increase
in the incidence of GE was identified in patients
with renal transplants receiving nifedipine along
with cyclosporine A compared with those using only
cyclosporine A (51% vs. 8%).26 Other reports have
shown an increased prevalence and severity of GE in
patients with renal transplants using both drugs. It was
stated that local and pharmacological factors were not
connected to enlargement and reported a trend for HLAA19-positive patients with unexplainable fingings of GE
that are related to underlying genetic predisposition.28
Another report by Slavin and Taylor 26 found that
patients with renal transplants using both cyclosporine
A and nifedipine had more severe GE than did patients
using only cyclosporine A. Bökenkamp et al.29 and Elias
et al.30 found that the incidence of GE was increased
when nifedipine was added into the trio of drugs
(cyclosporine A, prednisolone, and azithromycin).
Bökenkamp et al.29 also observed that GE was reduced
after nifedipine withdrawal in addition to good oral
hygiene with using chlorhexidine gel.
Karpinia et al.31 observed significantly higher degrees
of GE in children treated with cyclosporine A and
nifedipine than in those treated only with cyclosporine
A. Similarly, in our meta-analysis, the prevalence of GE
based on cyclosporine A was 62.6%. Among patients
using cyclosporine A along with nifedipine, gingival
growth prevalence was higher at 88.2%.
Prokurat et al.32 and Silverstein et al.33 used similar drugs
in their study. Silverstein et al.33 also used nifedipine.
With the use of nifedipine, the incidence of GE was
higher than that reported by Prokurat et al32.
Pizzo et al.34 also reported that the simultaneous use of
cyclosporine A and nifedipine in patients with renal
transplants significantly increased the prevalence and
severity of GE. They also suggested that this increase
enabled that the combination of nifedipine potentiates
the effects of cyclosporine A on gingiva.
As observed in Table 1, the prevalence of GE in the
study by Elias et al.30 was significantly higher than
that in the other studies, whereas Webb et al reported
the lowest prevalence of GE.35 In addition, the crosssectional studies were predominantly European studies
reporting about GE. The studies from Poland and France
had more patient numbers.32,36 According to the results
of our analysis, there was no significant difference
between subgroups based on the time interval between
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renal transplantation and gingival evaluation (≥6 months
vs.<6 months) (P = 0.921). As seen in the study by Elias
et al,30 which also had the highest prevalence, prior drug
history was considered to be >6 months. However, in
the study by Bökenkamp et al,29 the prevalence was
lower although the prior drug history was >12 months
and drug types were the same.
Children and adolescents are more frequently affected
by drug-induced GE as compared to adults. Drugs effect
to androgen and testosterone metabolism that was
indicated as a remarkable factor in the pathogenesis
of drug induced GE. In the same way, the excision of
the tissue from nifedipine and cyclosporine-induced
GE shows similar increase in androgen metabolism.37
Hence, we preferred to research previous studies about
transplantation in children.

5.
6.

7.
8.

9.

CONCLUSION
In conclusion, drug-induced GE similarly appears in
clinical practice, and its histological appearance is very
similar to that seen in the present study. Further studies
can help clarify the interactions between other drugs that
cause GE. The incidence of GE will increase if using
the aforementioned drugs; therefore, it is important for
all dentists to know the effects of these drugs and their
treatment options. Dental evaluation in a service would
be helpful for children undergoing transplant. Increase
in incidence and effectiveness of tooth brushing
from a younger age would help avoid GE in children
undergoing treatment with the aforementioned drugs.
The incidence of periodontal disorders would also
decrease in adulthood.
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